block grants management and administration operational issues and activities.

Dated: January 19, 2001.

Olivia A. Golden,

Assistant Secretary for Children and Families.

[FR Doc. 01–2464 Filed 1–26–01; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96M–0311]

''PHS Guideline on Infectious Disease Issues in Xenotransplantation;'' Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: On behalf of the U.S. Public Health Service (PHS), the Food and Drug Administration (FDA) is announcing the availability of a guideline entitled ''PHS Guideline on Infectious Disease Issues in Xenotransplantation'' dated January 19, 2001. This guideline was developed by the PHS to identify general principles for the prevention and control of infectious diseases associated with xenotransplantation that may pose a hazard to public health. The guideline is intended to provide general guidance to local review bodies evaluating proposed xenotransplantation protocols and to sponsors in developing xenotransplantation protocols, in preparing submissions to FDA and the Secretary's Advisory Committee on Xenotransplantation, and in conducting xenotransplantation clinical trials. The guideline announced in this document finalizes the ''Draft Public Health Service (PHS) Guideline on Infectious Disease Issues in Xenotransplantation'' announced in the **Federal Register** of September 23, 1996, as revised in response to comments.

DATES: Submit written comments at any time.

ADDRESSES: Submit written requests for single copies of the ''PHS Guideline on Infectious Disease Issues in Xenotransplantation'' dated January 19, 2001, to the Office of Communication, Training, and Manufacturers Assistance (HFM–40), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448. Send one self-addressed adhesive label to assist the office in processing your requests. The document may also be obtained by mail by calling the CBER Voice Information System at 1–800–835–4709 or 301–827–1800, or by fax by calling the Fax Information System at 1–888–CBER–FAX or 301–827–3844. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guideline.

Submit written comments on the guideline to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Stephen M. Ripley, Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–6210.

SUPPLEMENTARY INFORMATION:

I. Background

On behalf of the PHS, FDA is announcing the availability of a document entitled ''PHS Guideline on Infectious Disease Issues in Xenotransplantation'' dated January 19, 2001. This guideline was jointly developed by agencies within the PHS of the Department of Health and Human Services (DHHS), including FDA, the Centers for Disease Control and Prevention, the Health Resources and Services Administration, the National Institutes of Health, as well as the DHHS Office of the Assistant Secretary for Planning and Evaluation. This guideline is intended to identify general principles for the prevention and control of infectious diseases associated with xenotransplantation that may pose a hazard to public health. It is intended to provide general guidance to local review bodies evaluating proposed xenotransplantation protocols and to sponsors in developing xenotransplantation protocols, in preparing submissions to FDA and the Secretary's Advisory Committee on Xenotransplantation, and in conducting xenotransplantation clinical trials. Such clinical trials conducted within the United States are subject to regulation by FDA under the Public Health Service Act (42 U.S.C. 262, 264), and the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321 *et seq.*).

The finalized guideline announced in this document was revised based on public comments received in response to the ''Draft Public Health Service (PHS) Guideline on Infectious Disease Issues in Xenotransplantation'' announced in the **Federal Register** of September 23, 1996 (61 FR49920), as well as on input from national and international conferences and workshops. The preamble to the final guideline provides a summary of the major revisions and clarifications made to the draft guideline.

In the **Federal Register** of May 26, 2000 (65 FR 34196), FDA, on behalf of PHS, published a notice of the proposed reporting and recordkeeping requirements associated with the implementation of the guideline and provided an opportunity for public comment on the paperwork burden estimates for the guideline.

In the **Federal Register** of October 18, 2000 (65 FR 62359), FDA, on behalf of PHS, announced the submission of the reporting and recordkeeping burden estimates to the Office and Management and Budget for review and clearance under the Paperwork Reduction Act of 1995. The information collection provisions related to this guideline have been approved under OMB control number 0910–0456. This approval expires January 31, 2004. An agency may not conduct or sponsor, and a person is not obligated to respond to, a collection of information unless it displays a currently valid OMB control number.

This guideline represents PHS' current thinking on certain infectious disease issues in xenotransplantation. It does not create or confer any rights for or on any person and does not operate to bind the PHS or the public. This guideline is not intended to set forth an approach that addresses all of the potential health hazards related to infectious disease issues in xenotransplantation nor to establish the only way in which the public health hazards that are identified in this document may be addressed. The PHS acknowledges that not all of the recommendations set forth within this document may be fully relevant to all xenotransplantation products or xenotransplantation procedures. Sponsors of clinical xenotransplantation trials are advised to confer with relevant authorities (FDA, other reviewing authorities, funding sources, etc.) in assessing the relevance and appropriate adaptation of the general guidance offered here to specific clinical applications.

II. Comments

Interested persons may submit to the Dockets Management Branch (address above) written comments on the guideline. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in the brackets in the heading of this document. A copy of the guideline document and received comments are available for public examination in the Dockets

Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

III. Electronic Access

Persons with access to the Internet may obtain the guideline at http://www.fda.gov/cber/guidelines.htm.

Dated: December 26, 2000.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 01–2419 Filed 1–26–01; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF THE INTERIOR

Geological Survey

Technology Transfer Act of 1986

AGENCY: Geological Survey, Interior.

ACTION: Notice of Proposed Cooperative Research & Development Agreement (CRADA) Negotiations.

SUMMARY: The United States Geological Survey (USGS) is contemplating entering into a Cooperative Research and Development Agreement (CRADA) with E.I. du Pont de Nemours & Co., Inc. to develop a better understanding of the chemical composition of archived stream drainage sediment and soil samples.

Inquiries: If any other parties are interested in similar activities with the USGS, please contact: Andrew E. Grosz, USGS National Center, MS 954, 12201 Sunrise Valley Dr., Reston VA 20192, (703) 648–6314.

SUPPLEMENTARY INFORMATION: This notice is submitted to meet the USGS requirements stipulated in Survey Manual Chapter 500.20.

P. Patrick Leahy,

Associate Director for Geology, U.S. Geological Survey, Reston VA.

[FR Doc. 01–2420 Filed 1–26–01; 8:45 am]

BILLING CODE 4310–Y7–M

DEPARTMENT OF JUSTICE

National Institute of Corrections

Advisory Board Meeting

Time and Date: 8:30 a.m. to 5 p.m. on Monday, March 12, 2001 & 8 a.m. to 12 noon on Tuesday, March 13, 2001.

Place: Wyndham City Center Hotel, 1143 New Hampshire Avenue NW., Washington, DC 20037.

Status: Open.

Matters to be Considered: Fiscal Year 2002 Service Plan Recommendations, Updates on Mental Health Program Options and Interstate Compact Activities; and Results of Advisory Board Hearings.

Contact Person for More Information: Larry Solomon, Deputy Director, 202–307–3106, ext. 155.

Larry Solomon,

Deputy Director.

[FR Doc. 01–2422 Filed 1–26–01; 8:45 am]

BILLING CODE 4410–36–M

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice 01–018]

NASA Advisory Council (NAC), Aero-Space Technology Advisory Committee (ASTAC); Meeting

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, Pub. L. 92–463, as amended, the National Aeronautics and Space Administration announces a forthcoming meeting of the NASA Advisory Council, Aero-Space Technology Advisory Committee.

DATES: Wednesday, February 28, 2001, 8 a.m. to 4:30 p.m.; and Thursday, March 1, 2001, 8 a.m. to 12 Noon.

ADDRESSES: National Aeronautics and Space Administration, George C. Marshall Space Flight Center, Headquarters Building 4200, Room P–110, Marshall Space Flight Center, AL 35812.

FOR FURTHER INFORMATION CONTACT: Ms. Mary-Ellen McGrath, Office of Aerospace Technology, National Aeronautics and Space Administration, Washington, DC 20546 (202/358–4729).

SUPPLEMENTARY INFORMATION: The meeting will be open to the public up to the seating capacity of the room. The agenda for the meeting is as follows:

—ASTAC Restructuring Strategy

—Space Launch Initiative (SLI) Program

—Aviation Safety Research

—Government Performance Results Act (GPRA) 2001 Status

—Reports from Goals and Propulsion Subcommittees

—George C. Marshall Space Flight Center Tour

It is imperative that the meeting be held on these dates to accommodate the scheduling priorities of the key participants.

Dated: January 24, 2001.

Beth M. McCormick,

Advisory Committee Management Officer, National Aeronautics and Space Administration.

[FR Doc. 01–2482 Filed 1–26–01; 8:45 am]

BILLING CODE 7510–01–U

NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

National Endowment for the Arts; Leadership Initiatives Advisory Panel

Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), as amended, notice is hereby given that a meeting of the Leadership Initiatives Advisory Panel (Media Arts section B, Arts on Radio and Television category), to the National Council on the Arts will be held on January 31, 2001. The meeting will be held by teleconference at 2:30 p.m. in Room 726 at the Nancy Hanks Center, 1100 Pennsylvania Avenue, NW, Washington, DC 20506.

This meeting is for the purpose of Panel review, discussion, evaluation, and recommendations on financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as amended, including information given in confidence to the agency. In accordance with the determination of the Chairman of May 12, 2000, these sessions will be closed to the public pursuant to subsection (c)(4), (6) and (9)(B) of section 552b of Title 5, United States Code.

Further information with reference to this meeting can be obtained from Ms. Kathy Plowitz-Worden, Office of Guidelines & Panel Operations, National Endowment for the Arts, Washington, DC 20506, or call 202/682–5691.

Dated: January 24, 2001.

Kathy Plowitz-Worden,

Panel Coordinator, Panel Operations, National Endowment for the Arts.

[FR Doc. 01–2486 Filed 1–26–01; 8:45 am]

BILLING CODE 7537–01–U